EDIT - Editas to sell natural killer cell programs to Shoreline

• Editas Medicine ( NASDAQ: EDIT ) announced an agreement with privately-held Shoreline Biosciences on Thursday to sell its natural killer cell ((iNK)) programs and related manufacturing technologies.
• As part of the deal, Shoreline will also obtain an exclusive license to Editas’ ( EDIT ) SLEEK (SeLection by Essential-gene Exon Knock-in) gene editing knock-in technology and a non-exclusive license to its engineered AsCas12a gene editing technologies.
• Per the terms, Shoreline will acquire EDIT-202, a pre-clinical multiplexed edited iNK cell medicine developed by Editas ( EDIT ) for solid tumors, another experimental iNK program, and certain related manufacturing technologies.
• In addition to development/ commercial milestones and royalty payments, Shoreline is expected to pay Editas ( EDIT ) an upfront payment at the close of the deal.
• The sale of oncology assets is part of Editas’ ( EDIT ) recently announced portfolio reorganization targeted at hemoglobinopathies and in vivo gene editing.

For further details see: